In addition to recommendations on alternate techniques, the revised guideline, being jointly developed by CAP, IASLC, and AMP, will also include testing for emerging biomarkers in lung cancer.
The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology are teaming to revise the evidence-based guideline, “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors.”
The updated guideline will include new recommendations for ALK testing by IHC, ALK-EGFR resistance, and a number of emerging target molecular targets which will include, but is not limited to, ROS1, MET, ERBB2, RET, NTRK1. Multiplexed "Next Generation Sequencing" multigene panels and the reassessment of immunohistochemistry will be reviewed. The role of rebiopsy and repeat analysis in the setting of post-treatment relapse, along with testing of blood samples for mutations in circulating tumor cells, cell free tumor DNA, or exosomes will be considered.
Link to the report on MarketWatch: http://on.mktw.net/1xoSj3t